Roche partners with Zealand Pharma to advance petrelintide in obesity treatment

Pallavi Madhiraju- March 18, 2025 0

Roche has entered into an exclusive collaboration and licensing agreement with Zealand Pharma to develop and commercialise petrelintide obesity treatment, a promising amylin analog therapy ... Read More

Recursion Pharmaceuticals’ stock plunges 7% after shock Q4 loss – What went wrong?

Pallavi Madhiraju- February 28, 2025 0

Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, reported a significantly wider loss for the fourth quarter of 2024. The company’s ... Read More

Roche’s Gazyva shows superior efficacy in lupus nephritis treatment, Phase III trial data reveals

Pallavi Madhiraju- February 9, 2025 0

Roche has announced promising new data from its phase III REGENCY clinical trial, published in the New England Journal of Medicine, highlighting the superior efficacy ... Read More

Roche secures FDA approval for HER2-ultralow metastatic breast cancer diagnostic

Pallavi Madhiraju- February 2, 2025 0

Roche has received FDA approval for an expanded use of its PATHWAY HER2 (4B5) test, marking a significant breakthrough in breast cancer diagnostics. This development ... Read More

Innovent Biologics and Roche partner to advance DLL3 antibody drug conjugate

Pallavi Madhiraju- January 2, 2025 0

Innovent Biologics, Inc., a biopharmaceutical company, has entered a strategic global licensing agreement with Roche to propel the development of IBI3009, a novel DLL3-targeted antibody-drug ... Read More

Cancer treatment just got faster: FDA approves Genentech’s Tecentriq Hybreza for quick 7-minute injection

Pallavi Madhiraju- September 13, 2024 0

The U.S. Food and Drug Administration (FDA) has granted approval for Tecentriq Hybreza, the first and only PD-(L)1 inhibitor for subcutaneous injection, developed by Genentech, ... Read More

Phanes Therapeutics’ PT217 receives FDA orphan drug designation for neuroendocrine carcinoma

Pallavi Madhiraju- August 18, 2024 0

Phanes Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing oncology treatments, has achieved a significant milestone with the granting of Orphan Drug Designation (ODD) ... Read More

Dr. Reddy’s Laboratories secures key European endorsement for Rituximab biosimilar

Pallavi Madhiraju- July 30, 2024 0

In a significant development for the pharmaceutical industry, Dr. Reddy’s Laboratories Ltd. has received a positive opinion from the European Medicines Agency’s (EMA) Committee for ... Read More

How Roche’s new deal with LumiraDx will transform Point of Care testing forever

Pallavi Madhiraju- July 29, 2024 0

Roche Holding AG has finalised its acquisition of LumiraDx’s innovative Point of Care technology, a strategic move aimed at enhancing its diagnostic portfolio and expanding ... Read More

Breakthrough in diabetes care: Roche’s Susvimo could revolutionize eye treatment

Pallavi Madhiraju- July 20, 2024 0

Roche, a global leader in pharmaceuticals and diagnostics, recently unveiled two-year data from the pivotal Phase III Pagoda and Pavilion studies, showcasing the sustained efficacy ... Read More

123...610 / 60 Posts